nodes	percent_of_prediction	percent_of_DWPC	metapath
Nefazodone—HTR2A—coronary artery disease	0.132	1	CbGaD
Nefazodone—HTR1A—Penbutolol—coronary artery disease	0.0351	0.0655	CbGbCtD
Nefazodone—CYP3A7-CYP3A51P—Eplerenone—coronary artery disease	0.0226	0.0421	CbGbCtD
Nefazodone—CYP3A7—Eplerenone—coronary artery disease	0.0226	0.0421	CbGbCtD
Nefazodone—ABCB1—Ticagrelor—coronary artery disease	0.0192	0.0358	CbGbCtD
Nefazodone—CYP3A5—Clopidogrel—coronary artery disease	0.0182	0.034	CbGbCtD
Nefazodone—CYP3A5—Eplerenone—coronary artery disease	0.0169	0.0316	CbGbCtD
Nefazodone—CYP3A7-CYP3A51P—Simvastatin—coronary artery disease	0.0146	0.0271	CbGbCtD
Nefazodone—CYP3A7—Simvastatin—coronary artery disease	0.0146	0.0271	CbGbCtD
Nefazodone—CYP3A7—Lovastatin—coronary artery disease	0.0142	0.0265	CbGbCtD
Nefazodone—CYP3A7-CYP3A51P—Lovastatin—coronary artery disease	0.0142	0.0265	CbGbCtD
Nefazodone—CYP3A7—Atorvastatin—coronary artery disease	0.013	0.0242	CbGbCtD
Nefazodone—CYP3A7-CYP3A51P—Atorvastatin—coronary artery disease	0.013	0.0242	CbGbCtD
Nefazodone—ABCB1—Clopidogrel—coronary artery disease	0.0119	0.0221	CbGbCtD
Nefazodone—ABCB1—Perindopril—coronary artery disease	0.0119	0.0221	CbGbCtD
Nefazodone—CYP3A5—Rosuvastatin—coronary artery disease	0.0117	0.0219	CbGbCtD
Nefazodone—CYP3A4—Ticagrelor—coronary artery disease	0.0115	0.0214	CbGbCtD
Nefazodone—CYP3A5—Simvastatin—coronary artery disease	0.0109	0.0203	CbGbCtD
Nefazodone—CYP3A5—Pravastatin—coronary artery disease	0.0107	0.0199	CbGbCtD
Nefazodone—CYP3A5—Lovastatin—coronary artery disease	0.0107	0.0199	CbGbCtD
Nefazodone—ABCB1—Pitavastatin—coronary artery disease	0.0104	0.0193	CbGbCtD
Nefazodone—ABCB1—Telmisartan—coronary artery disease	0.0104	0.0193	CbGbCtD
Nefazodone—CYP3A4—Fenofibrate—coronary artery disease	0.0103	0.0191	CbGbCtD
Nefazodone—ABCB1—Enalapril—coronary artery disease	0.00983	0.0183	CbGbCtD
Nefazodone—ABCB1—Lisinopril—coronary artery disease	0.00983	0.0183	CbGbCtD
Nefazodone—CYP3A5—Atorvastatin—coronary artery disease	0.00973	0.0181	CbGbCtD
Nefazodone—CYP3A5—Losartan—coronary artery disease	0.0089	0.0166	CbGbCtD
Nefazodone—CYP2D6—Niacin—coronary artery disease	0.00847	0.0158	CbGbCtD
Nefazodone—ABCB1—Timolol—coronary artery disease	0.00836	0.0156	CbGbCtD
Nefazodone—CYP3A4—Gemfibrozil—coronary artery disease	0.0082	0.0153	CbGbCtD
Nefazodone—CYP2D6—Timolol—coronary artery disease	0.00787	0.0147	CbGbCtD
Nefazodone—ABCB1—Ezetimibe—coronary artery disease	0.00764	0.0142	CbGbCtD
Nefazodone—ABCB1—Acetylsalicylic acid—coronary artery disease	0.00745	0.0139	CbGbCtD
Nefazodone—ABCB1—Captopril—coronary artery disease	0.00736	0.0137	CbGbCtD
Nefazodone—CYP3A4—Clopidogrel—coronary artery disease	0.00711	0.0132	CbGbCtD
Nefazodone—ABCB1—Simvastatin—coronary artery disease	0.00711	0.0132	CbGbCtD
Nefazodone—ABCB1—Lovastatin—coronary artery disease	0.00695	0.013	CbGbCtD
Nefazodone—ABCB1—Pravastatin—coronary artery disease	0.00695	0.013	CbGbCtD
Nefazodone—CYP2D6—Captopril—coronary artery disease	0.00693	0.0129	CbGbCtD
Nefazodone—CYP2D6—Simvastatin—coronary artery disease	0.0067	0.0125	CbGbCtD
Nefazodone—CYP3A4—Eplerenone—coronary artery disease	0.00661	0.0123	CbGbCtD
Nefazodone—CYP2D6—Lovastatin—coronary artery disease	0.00655	0.0122	CbGbCtD
Nefazodone—CYP2D6—Pravastatin—coronary artery disease	0.00655	0.0122	CbGbCtD
Nefazodone—ABCB1—Atorvastatin—coronary artery disease	0.00633	0.0118	CbGbCtD
Nefazodone—CYP2D6—Atorvastatin—coronary artery disease	0.00597	0.0111	CbGbCtD
Nefazodone—CYP3A4—Enalapril—coronary artery disease	0.00589	0.011	CbGbCtD
Nefazodone—ABCB1—Losartan—coronary artery disease	0.00579	0.0108	CbGbCtD
Nefazodone—CYP3A4—Rosuvastatin—coronary artery disease	0.00458	0.00853	CbGbCtD
Nefazodone—CYP3A4—Ezetimibe—coronary artery disease	0.00458	0.00853	CbGbCtD
Nefazodone—CYP3A4—Simvastatin—coronary artery disease	0.00426	0.00793	CbGbCtD
Nefazodone—CYP3A4—Lovastatin—coronary artery disease	0.00417	0.00776	CbGbCtD
Nefazodone—CYP3A4—Pravastatin—coronary artery disease	0.00417	0.00776	CbGbCtD
Nefazodone—CYP3A4—Atorvastatin—coronary artery disease	0.00379	0.00707	CbGbCtD
Nefazodone—CYP3A4—Losartan—coronary artery disease	0.00347	0.00647	CbGbCtD
Nefazodone—SLC6A2—sympathetic nervous system—coronary artery disease	0.00254	0.138	CbGeAlD
Nefazodone—HTR2A—arteriole—coronary artery disease	0.0024	0.13	CbGeAlD
Nefazodone—SLC6A2—autonomic nervous system—coronary artery disease	0.00171	0.0929	CbGeAlD
Nefazodone—HTR2A—pulmonary artery—coronary artery disease	0.00157	0.0854	CbGeAlD
Nefazodone—HTR2A—sympathetic nervous system—coronary artery disease	0.00153	0.0831	CbGeAlD
Nefazodone—HTR2A—vagus nerve—coronary artery disease	0.00148	0.0805	CbGeAlD
Nefazodone—HTR2A—vein—coronary artery disease	0.00143	0.0777	CbGeAlD
Nefazodone—HTR2A—autonomic nervous system—coronary artery disease	0.00103	0.0558	CbGeAlD
Nefazodone—HTR2A—artery—coronary artery disease	0.000583	0.0317	CbGeAlD
Nefazodone—HTR2A—endothelium—coronary artery disease	0.000492	0.0267	CbGeAlD
Nefazodone—HTR1A—cardiovascular system—coronary artery disease	0.00034	0.0185	CbGeAlD
Nefazodone—ADRA1A—heart—coronary artery disease	0.000332	0.018	CbGeAlD
Nefazodone—ADRA1A—cardiovascular system—coronary artery disease	0.000313	0.017	CbGeAlD
Nefazodone—SLC6A4—blood—coronary artery disease	0.000303	0.0164	CbGeAlD
Nefazodone—ADRA2A—heart—coronary artery disease	0.000252	0.0137	CbGeAlD
Nefazodone—ADRA1A—blood—coronary artery disease	0.000248	0.0135	CbGeAlD
Nefazodone—Aripiprazole—HTR7—coronary artery disease	0.000223	0.131	CrCbGaD
Nefazodone—ADRA2A—cardiac atrium—coronary artery disease	0.000216	0.0117	CbGeAlD
Nefazodone—HTR2A—heart—coronary artery disease	0.000215	0.0117	CbGeAlD
Nefazodone—HTR2A—cardiovascular system—coronary artery disease	0.000202	0.011	CbGeAlD
Nefazodone—CYP3A5—blood—coronary artery disease	0.000198	0.0107	CbGeAlD
Nefazodone—Aripiprazole—ADRB1—coronary artery disease	0.000191	0.112	CrCbGaD
Nefazodone—ADRA2A—blood—coronary artery disease	0.000188	0.0102	CbGeAlD
Nefazodone—HTR2A—blood—coronary artery disease	0.00016	0.0087	CbGeAlD
Nefazodone—CYP3A4—blood—coronary artery disease	0.000148	0.00806	CbGeAlD
Nefazodone—CYP2D6—blood—coronary artery disease	0.000146	0.00793	CbGeAlD
Nefazodone—Perphenazine—HTR7—coronary artery disease	0.000142	0.0837	CrCbGaD
Nefazodone—ABCB1—heart—coronary artery disease	0.000141	0.00764	CbGeAlD
Nefazodone—Quetiapine—HTR7—coronary artery disease	0.000139	0.0821	CrCbGaD
Nefazodone—ABCB1—cardiovascular system—coronary artery disease	0.000133	0.00721	CbGeAlD
Nefazodone—Zuclopenthixol—HTR2A—coronary artery disease	0.000121	0.0714	CrCbGaD
Nefazodone—Aripiprazole—HTR2A—coronary artery disease	0.000112	0.066	CrCbGaD
Nefazodone—Trazodone—HTR2A—coronary artery disease	0.000112	0.0657	CrCbGaD
Nefazodone—Thioproperazine—HTR2A—coronary artery disease	0.000106	0.0626	CrCbGaD
Nefazodone—ABCB1—blood—coronary artery disease	0.000105	0.0057	CbGeAlD
Nefazodone—Fluphenazine—HTR2A—coronary artery disease	9.03e-05	0.0532	CrCbGaD
Nefazodone—Perphenazine—CYP2C19—coronary artery disease	8.81e-05	0.0519	CrCbGaD
Nefazodone—Quetiapine—CYP2C19—coronary artery disease	8.64e-05	0.0509	CrCbGaD
Nefazodone—Thioproperazine—ALB—coronary artery disease	7.27e-05	0.0428	CrCbGaD
Nefazodone—Trifluoperazine—HTR2A—coronary artery disease	7.22e-05	0.0425	CrCbGaD
Nefazodone—Perphenazine—HTR2A—coronary artery disease	7.14e-05	0.0421	CrCbGaD
Nefazodone—Quetiapine—HTR2A—coronary artery disease	7e-05	0.0413	CrCbGaD
Nefazodone—Angioedema—Lisinopril—coronary artery disease	5.26e-05	0.000248	CcSEcCtD
Nefazodone—Pruritus—Olmesartan—coronary artery disease	5.26e-05	0.000248	CcSEcCtD
Nefazodone—Decreased appetite—Losartan—coronary artery disease	5.25e-05	0.000248	CcSEcCtD
Nefazodone—Abdominal pain—Captopril—coronary artery disease	5.24e-05	0.000248	CcSEcCtD
Nefazodone—Body temperature increased—Captopril—coronary artery disease	5.24e-05	0.000248	CcSEcCtD
Nefazodone—Dizziness—Simvastatin—coronary artery disease	5.23e-05	0.000247	CcSEcCtD
Nefazodone—Rash—Ezetimibe—coronary artery disease	5.23e-05	0.000247	CcSEcCtD
Nefazodone—Dermatitis—Ezetimibe—coronary artery disease	5.22e-05	0.000247	CcSEcCtD
Nefazodone—Confusional state—Ramipril—coronary artery disease	5.22e-05	0.000247	CcSEcCtD
Nefazodone—Discomfort—Timolol—coronary artery disease	5.22e-05	0.000246	CcSEcCtD
Nefazodone—Asthenia—Niacin—coronary artery disease	5.21e-05	0.000246	CcSEcCtD
Nefazodone—Headache—Ezetimibe—coronary artery disease	5.19e-05	0.000245	CcSEcCtD
Nefazodone—Malaise—Lisinopril—coronary artery disease	5.19e-05	0.000245	CcSEcCtD
Nefazodone—Anaphylactic shock—Ramipril—coronary artery disease	5.18e-05	0.000245	CcSEcCtD
Nefazodone—Oedema—Ramipril—coronary artery disease	5.18e-05	0.000245	CcSEcCtD
Nefazodone—Vertigo—Lisinopril—coronary artery disease	5.17e-05	0.000244	CcSEcCtD
Nefazodone—Dry mouth—Timolol—coronary artery disease	5.16e-05	0.000244	CcSEcCtD
Nefazodone—Constipation—Losartan—coronary artery disease	5.16e-05	0.000244	CcSEcCtD
Nefazodone—Pain—Losartan—coronary artery disease	5.16e-05	0.000244	CcSEcCtD
Nefazodone—Syncope—Lisinopril—coronary artery disease	5.16e-05	0.000244	CcSEcCtD
Nefazodone—Vomiting—Eplerenone—coronary artery disease	5.16e-05	0.000244	CcSEcCtD
Nefazodone—Feeling abnormal—Furosemide—coronary artery disease	5.16e-05	0.000244	CcSEcCtD
Nefazodone—Leukopenia—Lisinopril—coronary artery disease	5.15e-05	0.000243	CcSEcCtD
Nefazodone—Nausea—Fenofibrate—coronary artery disease	5.14e-05	0.000243	CcSEcCtD
Nefazodone—Pruritus—Niacin—coronary artery disease	5.14e-05	0.000243	CcSEcCtD
Nefazodone—Asthenia—Pravastatin—coronary artery disease	5.13e-05	0.000242	CcSEcCtD
Nefazodone—Gastrointestinal pain—Furosemide—coronary artery disease	5.12e-05	0.000242	CcSEcCtD
Nefazodone—Rash—Eplerenone—coronary artery disease	5.12e-05	0.000242	CcSEcCtD
Nefazodone—Urticaria—Perindopril—coronary artery disease	5.11e-05	0.000242	CcSEcCtD
Nefazodone—Hypersensitivity—Trandolapril—coronary artery disease	5.11e-05	0.000242	CcSEcCtD
Nefazodone—Dermatitis—Eplerenone—coronary artery disease	5.11e-05	0.000241	CcSEcCtD
Nefazodone—Diarrhoea—Valsartan—coronary artery disease	5.11e-05	0.000241	CcSEcCtD
Nefazodone—Confusional state—Timolol—coronary artery disease	5.1e-05	0.000241	CcSEcCtD
Nefazodone—Shock—Ramipril—coronary artery disease	5.09e-05	0.000241	CcSEcCtD
Nefazodone—Hypersensitivity—Enalapril—coronary artery disease	5.09e-05	0.000241	CcSEcCtD
Nefazodone—Abdominal pain—Perindopril—coronary artery disease	5.09e-05	0.00024	CcSEcCtD
Nefazodone—Body temperature increased—Perindopril—coronary artery disease	5.09e-05	0.00024	CcSEcCtD
Nefazodone—Palpitations—Lisinopril—coronary artery disease	5.08e-05	0.00024	CcSEcCtD
Nefazodone—Diarrhoea—Olmesartan—coronary artery disease	5.08e-05	0.00024	CcSEcCtD
Nefazodone—Headache—Eplerenone—coronary artery disease	5.08e-05	0.00024	CcSEcCtD
Nefazodone—Thrombocytopenia—Ramipril—coronary artery disease	5.07e-05	0.000239	CcSEcCtD
Nefazodone—Oedema—Timolol—coronary artery disease	5.06e-05	0.000239	CcSEcCtD
Nefazodone—Anaphylactic shock—Timolol—coronary artery disease	5.06e-05	0.000239	CcSEcCtD
Nefazodone—Pruritus—Pravastatin—coronary artery disease	5.06e-05	0.000239	CcSEcCtD
Nefazodone—Loss of consciousness—Lisinopril—coronary artery disease	5.06e-05	0.000239	CcSEcCtD
Nefazodone—Nausea—Clopidogrel—coronary artery disease	5.05e-05	0.000239	CcSEcCtD
Nefazodone—Tachycardia—Ramipril—coronary artery disease	5.05e-05	0.000239	CcSEcCtD
Nefazodone—Infection—Timolol—coronary artery disease	5.03e-05	0.000238	CcSEcCtD
Nefazodone—Vomiting—Simvastatin—coronary artery disease	5.03e-05	0.000237	CcSEcCtD
Nefazodone—Hypersensitivity—Telmisartan—coronary artery disease	5.02e-05	0.000237	CcSEcCtD
Nefazodone—Cough—Lisinopril—coronary artery disease	5.02e-05	0.000237	CcSEcCtD
Nefazodone—Nausea—Lovastatin—coronary artery disease	5.02e-05	0.000237	CcSEcCtD
Nefazodone—Hyperhidrosis—Ramipril—coronary artery disease	5e-05	0.000236	CcSEcCtD
Nefazodone—Rash—Simvastatin—coronary artery disease	4.98e-05	0.000235	CcSEcCtD
Nefazodone—Dermatitis—Simvastatin—coronary artery disease	4.98e-05	0.000235	CcSEcCtD
Nefazodone—Asthenia—Trandolapril—coronary artery disease	4.98e-05	0.000235	CcSEcCtD
Nefazodone—Shock—Timolol—coronary artery disease	4.98e-05	0.000235	CcSEcCtD
Nefazodone—Feeling abnormal—Losartan—coronary artery disease	4.98e-05	0.000235	CcSEcCtD
Nefazodone—Urticaria—Furosemide—coronary artery disease	4.97e-05	0.000235	CcSEcCtD
Nefazodone—Diarrhoea—Niacin—coronary artery disease	4.97e-05	0.000235	CcSEcCtD
Nefazodone—Asthenia—Enalapril—coronary artery disease	4.96e-05	0.000234	CcSEcCtD
Nefazodone—Headache—Simvastatin—coronary artery disease	4.95e-05	0.000234	CcSEcCtD
Nefazodone—Abdominal pain—Furosemide—coronary artery disease	4.95e-05	0.000234	CcSEcCtD
Nefazodone—Body temperature increased—Furosemide—coronary artery disease	4.95e-05	0.000234	CcSEcCtD
Nefazodone—Gastrointestinal pain—Losartan—coronary artery disease	4.94e-05	0.000233	CcSEcCtD
Nefazodone—Dizziness—Valsartan—coronary artery disease	4.94e-05	0.000233	CcSEcCtD
Nefazodone—Anorexia—Ramipril—coronary artery disease	4.93e-05	0.000233	CcSEcCtD
Nefazodone—Nausea—Ezetimibe—coronary artery disease	4.92e-05	0.000233	CcSEcCtD
Nefazodone—Dizziness—Olmesartan—coronary artery disease	4.91e-05	0.000232	CcSEcCtD
Nefazodone—Pruritus—Trandolapril—coronary artery disease	4.91e-05	0.000232	CcSEcCtD
Nefazodone—Chest pain—Lisinopril—coronary artery disease	4.9e-05	0.000231	CcSEcCtD
Nefazodone—Myalgia—Lisinopril—coronary artery disease	4.9e-05	0.000231	CcSEcCtD
Nefazodone—Arthralgia—Lisinopril—coronary artery disease	4.9e-05	0.000231	CcSEcCtD
Nefazodone—Hyperhidrosis—Timolol—coronary artery disease	4.89e-05	0.000231	CcSEcCtD
Nefazodone—Asthenia—Telmisartan—coronary artery disease	4.89e-05	0.000231	CcSEcCtD
Nefazodone—Pruritus—Enalapril—coronary artery disease	4.89e-05	0.000231	CcSEcCtD
Nefazodone—Diarrhoea—Pravastatin—coronary artery disease	4.89e-05	0.000231	CcSEcCtD
Nefazodone—Anxiety—Lisinopril—coronary artery disease	4.88e-05	0.000231	CcSEcCtD
Nefazodone—Discomfort—Lisinopril—coronary artery disease	4.84e-05	0.000229	CcSEcCtD
Nefazodone—Hypotension—Ramipril—coronary artery disease	4.84e-05	0.000229	CcSEcCtD
Nefazodone—Anorexia—Timolol—coronary artery disease	4.82e-05	0.000228	CcSEcCtD
Nefazodone—Pruritus—Telmisartan—coronary artery disease	4.82e-05	0.000228	CcSEcCtD
Nefazodone—Nausea—Eplerenone—coronary artery disease	4.82e-05	0.000228	CcSEcCtD
Nefazodone—Dizziness—Niacin—coronary artery disease	4.8e-05	0.000227	CcSEcCtD
Nefazodone—Urticaria—Losartan—coronary artery disease	4.8e-05	0.000227	CcSEcCtD
Nefazodone—Dry mouth—Lisinopril—coronary artery disease	4.79e-05	0.000226	CcSEcCtD
Nefazodone—Body temperature increased—Losartan—coronary artery disease	4.77e-05	0.000225	CcSEcCtD
Nefazodone—Abdominal pain—Losartan—coronary artery disease	4.77e-05	0.000225	CcSEcCtD
Nefazodone—Asthenia—Captopril—coronary artery disease	4.76e-05	0.000225	CcSEcCtD
Nefazodone—Diarrhoea—Trandolapril—coronary artery disease	4.75e-05	0.000224	CcSEcCtD
Nefazodone—Vomiting—Valsartan—coronary artery disease	4.75e-05	0.000224	CcSEcCtD
Nefazodone—Confusional state—Lisinopril—coronary artery disease	4.73e-05	0.000224	CcSEcCtD
Nefazodone—Diarrhoea—Enalapril—coronary artery disease	4.73e-05	0.000223	CcSEcCtD
Nefazodone—Hypotension—Timolol—coronary artery disease	4.73e-05	0.000223	CcSEcCtD
Nefazodone—Dizziness—Pravastatin—coronary artery disease	4.73e-05	0.000223	CcSEcCtD
Nefazodone—Vomiting—Olmesartan—coronary artery disease	4.72e-05	0.000223	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Ramipril—coronary artery disease	4.72e-05	0.000223	CcSEcCtD
Nefazodone—Rash—Valsartan—coronary artery disease	4.71e-05	0.000222	CcSEcCtD
Nefazodone—Dermatitis—Valsartan—coronary artery disease	4.7e-05	0.000222	CcSEcCtD
Nefazodone—Nausea—Simvastatin—coronary artery disease	4.7e-05	0.000222	CcSEcCtD
Nefazodone—Anaphylactic shock—Lisinopril—coronary artery disease	4.7e-05	0.000222	CcSEcCtD
Nefazodone—Oedema—Lisinopril—coronary artery disease	4.7e-05	0.000222	CcSEcCtD
Nefazodone—Pruritus—Captopril—coronary artery disease	4.69e-05	0.000222	CcSEcCtD
Nefazodone—Rash—Olmesartan—coronary artery disease	4.68e-05	0.000221	CcSEcCtD
Nefazodone—Insomnia—Ramipril—coronary artery disease	4.68e-05	0.000221	CcSEcCtD
Nefazodone—Dermatitis—Olmesartan—coronary artery disease	4.68e-05	0.000221	CcSEcCtD
Nefazodone—Headache—Valsartan—coronary artery disease	4.68e-05	0.000221	CcSEcCtD
Nefazodone—Diarrhoea—Telmisartan—coronary artery disease	4.66e-05	0.00022	CcSEcCtD
Nefazodone—Infection—Lisinopril—coronary artery disease	4.66e-05	0.00022	CcSEcCtD
Nefazodone—Headache—Olmesartan—coronary artery disease	4.65e-05	0.00022	CcSEcCtD
Nefazodone—Paraesthesia—Ramipril—coronary artery disease	4.65e-05	0.00022	CcSEcCtD
Nefazodone—Shock—Lisinopril—coronary artery disease	4.62e-05	0.000218	CcSEcCtD
Nefazodone—Asthenia—Perindopril—coronary artery disease	4.62e-05	0.000218	CcSEcCtD
Nefazodone—Dyspnoea—Ramipril—coronary artery disease	4.62e-05	0.000218	CcSEcCtD
Nefazodone—Vomiting—Niacin—coronary artery disease	4.62e-05	0.000218	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Timolol—coronary artery disease	4.61e-05	0.000218	CcSEcCtD
Nefazodone—Hypersensitivity—Furosemide—coronary artery disease	4.61e-05	0.000218	CcSEcCtD
Nefazodone—Somnolence—Ramipril—coronary artery disease	4.6e-05	0.000217	CcSEcCtD
Nefazodone—Thrombocytopenia—Lisinopril—coronary artery disease	4.6e-05	0.000217	CcSEcCtD
Nefazodone—Dizziness—Trandolapril—coronary artery disease	4.59e-05	0.000217	CcSEcCtD
Nefazodone—Tachycardia—Lisinopril—coronary artery disease	4.58e-05	0.000216	CcSEcCtD
Nefazodone—Insomnia—Timolol—coronary artery disease	4.58e-05	0.000216	CcSEcCtD
Nefazodone—Rash—Niacin—coronary artery disease	4.58e-05	0.000216	CcSEcCtD
Nefazodone—Dermatitis—Niacin—coronary artery disease	4.57e-05	0.000216	CcSEcCtD
Nefazodone—Dizziness—Enalapril—coronary artery disease	4.57e-05	0.000216	CcSEcCtD
Nefazodone—Dyspepsia—Ramipril—coronary artery disease	4.56e-05	0.000215	CcSEcCtD
Nefazodone—Pruritus—Perindopril—coronary artery disease	4.55e-05	0.000215	CcSEcCtD
Nefazodone—Headache—Niacin—coronary artery disease	4.55e-05	0.000215	CcSEcCtD
Nefazodone—Paraesthesia—Timolol—coronary artery disease	4.54e-05	0.000215	CcSEcCtD
Nefazodone—Vomiting—Pravastatin—coronary artery disease	4.54e-05	0.000215	CcSEcCtD
Nefazodone—Hyperhidrosis—Lisinopril—coronary artery disease	4.54e-05	0.000214	CcSEcCtD
Nefazodone—Diarrhoea—Captopril—coronary artery disease	4.54e-05	0.000214	CcSEcCtD
Nefazodone—Dyspnoea—Timolol—coronary artery disease	4.51e-05	0.000213	CcSEcCtD
Nefazodone—Dizziness—Telmisartan—coronary artery disease	4.51e-05	0.000213	CcSEcCtD
Nefazodone—Rash—Pravastatin—coronary artery disease	4.51e-05	0.000213	CcSEcCtD
Nefazodone—Dermatitis—Pravastatin—coronary artery disease	4.5e-05	0.000213	CcSEcCtD
Nefazodone—Decreased appetite—Ramipril—coronary artery disease	4.5e-05	0.000213	CcSEcCtD
Nefazodone—Somnolence—Timolol—coronary artery disease	4.5e-05	0.000213	CcSEcCtD
Nefazodone—Asthenia—Furosemide—coronary artery disease	4.49e-05	0.000212	CcSEcCtD
Nefazodone—Headache—Pravastatin—coronary artery disease	4.48e-05	0.000212	CcSEcCtD
Nefazodone—Anorexia—Lisinopril—coronary artery disease	4.48e-05	0.000211	CcSEcCtD
Nefazodone—Dyspepsia—Timolol—coronary artery disease	4.46e-05	0.00021	CcSEcCtD
Nefazodone—Hypersensitivity—Losartan—coronary artery disease	4.45e-05	0.00021	CcSEcCtD
Nefazodone—Nausea—Valsartan—coronary artery disease	4.43e-05	0.000209	CcSEcCtD
Nefazodone—Pruritus—Furosemide—coronary artery disease	4.43e-05	0.000209	CcSEcCtD
Nefazodone—Constipation—Ramipril—coronary artery disease	4.43e-05	0.000209	CcSEcCtD
Nefazodone—Nausea—Olmesartan—coronary artery disease	4.41e-05	0.000208	CcSEcCtD
Nefazodone—Vomiting—Trandolapril—coronary artery disease	4.41e-05	0.000208	CcSEcCtD
Nefazodone—Diarrhoea—Perindopril—coronary artery disease	4.4e-05	0.000208	CcSEcCtD
Nefazodone—Decreased appetite—Timolol—coronary artery disease	4.4e-05	0.000208	CcSEcCtD
Nefazodone—Vomiting—Enalapril—coronary artery disease	4.4e-05	0.000208	CcSEcCtD
Nefazodone—Hypotension—Lisinopril—coronary artery disease	4.39e-05	0.000207	CcSEcCtD
Nefazodone—Dizziness—Captopril—coronary artery disease	4.38e-05	0.000207	CcSEcCtD
Nefazodone—Rash—Trandolapril—coronary artery disease	4.38e-05	0.000207	CcSEcCtD
Nefazodone—Dermatitis—Trandolapril—coronary artery disease	4.37e-05	0.000207	CcSEcCtD
Nefazodone—Rash—Enalapril—coronary artery disease	4.36e-05	0.000206	CcSEcCtD
Nefazodone—Dermatitis—Enalapril—coronary artery disease	4.35e-05	0.000206	CcSEcCtD
Nefazodone—Headache—Trandolapril—coronary artery disease	4.35e-05	0.000205	CcSEcCtD
Nefazodone—Vomiting—Telmisartan—coronary artery disease	4.33e-05	0.000205	CcSEcCtD
Nefazodone—Asthenia—Losartan—coronary artery disease	4.33e-05	0.000205	CcSEcCtD
Nefazodone—Headache—Enalapril—coronary artery disease	4.33e-05	0.000205	CcSEcCtD
Nefazodone—Pain—Timolol—coronary artery disease	4.33e-05	0.000204	CcSEcCtD
Nefazodone—Nausea—Niacin—coronary artery disease	4.31e-05	0.000204	CcSEcCtD
Nefazodone—Rash—Telmisartan—coronary artery disease	4.3e-05	0.000203	CcSEcCtD
Nefazodone—Dermatitis—Telmisartan—coronary artery disease	4.29e-05	0.000203	CcSEcCtD
Nefazodone—Diarrhoea—Furosemide—coronary artery disease	4.28e-05	0.000202	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Lisinopril—coronary artery disease	4.28e-05	0.000202	CcSEcCtD
Nefazodone—Pruritus—Losartan—coronary artery disease	4.27e-05	0.000202	CcSEcCtD
Nefazodone—Headache—Telmisartan—coronary artery disease	4.27e-05	0.000202	CcSEcCtD
Nefazodone—Feeling abnormal—Ramipril—coronary artery disease	4.27e-05	0.000202	CcSEcCtD
Nefazodone—Dizziness—Perindopril—coronary artery disease	4.26e-05	0.000201	CcSEcCtD
Nefazodone—Insomnia—Lisinopril—coronary artery disease	4.25e-05	0.000201	CcSEcCtD
Nefazodone—Nausea—Pravastatin—coronary artery disease	4.25e-05	0.000201	CcSEcCtD
Nefazodone—Gastrointestinal pain—Ramipril—coronary artery disease	4.23e-05	0.0002	CcSEcCtD
Nefazodone—Paraesthesia—Lisinopril—coronary artery disease	4.22e-05	0.000199	CcSEcCtD
Nefazodone—Vomiting—Captopril—coronary artery disease	4.22e-05	0.000199	CcSEcCtD
Nefazodone—Dyspnoea—Lisinopril—coronary artery disease	4.19e-05	0.000198	CcSEcCtD
Nefazodone—Rash—Captopril—coronary artery disease	4.18e-05	0.000197	CcSEcCtD
Nefazodone—Dermatitis—Captopril—coronary artery disease	4.18e-05	0.000197	CcSEcCtD
Nefazodone—Somnolence—Lisinopril—coronary artery disease	4.17e-05	0.000197	CcSEcCtD
Nefazodone—Feeling abnormal—Timolol—coronary artery disease	4.17e-05	0.000197	CcSEcCtD
Nefazodone—Headache—Captopril—coronary artery disease	4.15e-05	0.000196	CcSEcCtD
Nefazodone—Gastrointestinal pain—Timolol—coronary artery disease	4.14e-05	0.000196	CcSEcCtD
Nefazodone—Dizziness—Furosemide—coronary artery disease	4.14e-05	0.000195	CcSEcCtD
Nefazodone—Dyspepsia—Lisinopril—coronary artery disease	4.13e-05	0.000195	CcSEcCtD
Nefazodone—Diarrhoea—Losartan—coronary artery disease	4.13e-05	0.000195	CcSEcCtD
Nefazodone—Nausea—Trandolapril—coronary artery disease	4.12e-05	0.000195	CcSEcCtD
Nefazodone—Urticaria—Ramipril—coronary artery disease	4.11e-05	0.000194	CcSEcCtD
Nefazodone—Nausea—Enalapril—coronary artery disease	4.11e-05	0.000194	CcSEcCtD
Nefazodone—Vomiting—Perindopril—coronary artery disease	4.09e-05	0.000193	CcSEcCtD
Nefazodone—Abdominal pain—Ramipril—coronary artery disease	4.09e-05	0.000193	CcSEcCtD
Nefazodone—Body temperature increased—Ramipril—coronary artery disease	4.09e-05	0.000193	CcSEcCtD
Nefazodone—Decreased appetite—Lisinopril—coronary artery disease	4.08e-05	0.000193	CcSEcCtD
Nefazodone—Rash—Perindopril—coronary artery disease	4.06e-05	0.000192	CcSEcCtD
Nefazodone—Dermatitis—Perindopril—coronary artery disease	4.05e-05	0.000192	CcSEcCtD
Nefazodone—Nausea—Telmisartan—coronary artery disease	4.05e-05	0.000191	CcSEcCtD
Nefazodone—Headache—Perindopril—coronary artery disease	4.03e-05	0.00019	CcSEcCtD
Nefazodone—Urticaria—Timolol—coronary artery disease	4.02e-05	0.00019	CcSEcCtD
Nefazodone—Pain—Lisinopril—coronary artery disease	4.02e-05	0.00019	CcSEcCtD
Nefazodone—Constipation—Lisinopril—coronary artery disease	4.02e-05	0.00019	CcSEcCtD
Nefazodone—Abdominal pain—Timolol—coronary artery disease	4e-05	0.000189	CcSEcCtD
Nefazodone—Body temperature increased—Timolol—coronary artery disease	4e-05	0.000189	CcSEcCtD
Nefazodone—Dizziness—Losartan—coronary artery disease	3.99e-05	0.000189	CcSEcCtD
Nefazodone—Vomiting—Furosemide—coronary artery disease	3.98e-05	0.000188	CcSEcCtD
Nefazodone—Rash—Furosemide—coronary artery disease	3.95e-05	0.000186	CcSEcCtD
Nefazodone—Dermatitis—Furosemide—coronary artery disease	3.94e-05	0.000186	CcSEcCtD
Nefazodone—Nausea—Captopril—coronary artery disease	3.94e-05	0.000186	CcSEcCtD
Nefazodone—Headache—Furosemide—coronary artery disease	3.92e-05	0.000185	CcSEcCtD
Nefazodone—Feeling abnormal—Lisinopril—coronary artery disease	3.87e-05	0.000183	CcSEcCtD
Nefazodone—Gastrointestinal pain—Lisinopril—coronary artery disease	3.84e-05	0.000181	CcSEcCtD
Nefazodone—Vomiting—Losartan—coronary artery disease	3.84e-05	0.000181	CcSEcCtD
Nefazodone—Nausea—Perindopril—coronary artery disease	3.82e-05	0.000181	CcSEcCtD
Nefazodone—Hypersensitivity—Ramipril—coronary artery disease	3.81e-05	0.00018	CcSEcCtD
Nefazodone—Rash—Losartan—coronary artery disease	3.81e-05	0.00018	CcSEcCtD
Nefazodone—Dermatitis—Losartan—coronary artery disease	3.8e-05	0.00018	CcSEcCtD
Nefazodone—Headache—Losartan—coronary artery disease	3.78e-05	0.000179	CcSEcCtD
Nefazodone—Urticaria—Lisinopril—coronary artery disease	3.73e-05	0.000176	CcSEcCtD
Nefazodone—Hypersensitivity—Timolol—coronary artery disease	3.73e-05	0.000176	CcSEcCtD
Nefazodone—Nausea—Furosemide—coronary artery disease	3.72e-05	0.000176	CcSEcCtD
Nefazodone—Asthenia—Ramipril—coronary artery disease	3.71e-05	0.000175	CcSEcCtD
Nefazodone—Abdominal pain—Lisinopril—coronary artery disease	3.71e-05	0.000175	CcSEcCtD
Nefazodone—Body temperature increased—Lisinopril—coronary artery disease	3.71e-05	0.000175	CcSEcCtD
Nefazodone—Pruritus—Ramipril—coronary artery disease	3.66e-05	0.000173	CcSEcCtD
Nefazodone—Asthenia—Timolol—coronary artery disease	3.63e-05	0.000172	CcSEcCtD
Nefazodone—Nausea—Losartan—coronary artery disease	3.59e-05	0.000169	CcSEcCtD
Nefazodone—Pruritus—Timolol—coronary artery disease	3.58e-05	0.000169	CcSEcCtD
Nefazodone—Diarrhoea—Ramipril—coronary artery disease	3.54e-05	0.000167	CcSEcCtD
Nefazodone—Diarrhoea—Timolol—coronary artery disease	3.46e-05	0.000164	CcSEcCtD
Nefazodone—Hypersensitivity—Lisinopril—coronary artery disease	3.46e-05	0.000163	CcSEcCtD
Nefazodone—Dizziness—Ramipril—coronary artery disease	3.42e-05	0.000162	CcSEcCtD
Nefazodone—Asthenia—Lisinopril—coronary artery disease	3.37e-05	0.000159	CcSEcCtD
Nefazodone—Dizziness—Timolol—coronary artery disease	3.35e-05	0.000158	CcSEcCtD
Nefazodone—Pruritus—Lisinopril—coronary artery disease	3.32e-05	0.000157	CcSEcCtD
Nefazodone—Vomiting—Ramipril—coronary artery disease	3.29e-05	0.000155	CcSEcCtD
Nefazodone—Rash—Ramipril—coronary artery disease	3.26e-05	0.000154	CcSEcCtD
Nefazodone—Dermatitis—Ramipril—coronary artery disease	3.26e-05	0.000154	CcSEcCtD
Nefazodone—Headache—Ramipril—coronary artery disease	3.24e-05	0.000153	CcSEcCtD
Nefazodone—Vomiting—Timolol—coronary artery disease	3.22e-05	0.000152	CcSEcCtD
Nefazodone—Diarrhoea—Lisinopril—coronary artery disease	3.21e-05	0.000152	CcSEcCtD
Nefazodone—Rash—Timolol—coronary artery disease	3.19e-05	0.000151	CcSEcCtD
Nefazodone—Dermatitis—Timolol—coronary artery disease	3.19e-05	0.000151	CcSEcCtD
Nefazodone—Headache—Timolol—coronary artery disease	3.17e-05	0.00015	CcSEcCtD
Nefazodone—Dizziness—Lisinopril—coronary artery disease	3.1e-05	0.000147	CcSEcCtD
Nefazodone—Nausea—Ramipril—coronary artery disease	3.08e-05	0.000145	CcSEcCtD
Nefazodone—Nausea—Timolol—coronary artery disease	3.01e-05	0.000142	CcSEcCtD
Nefazodone—Vomiting—Lisinopril—coronary artery disease	2.99e-05	0.000141	CcSEcCtD
Nefazodone—Rash—Lisinopril—coronary artery disease	2.96e-05	0.00014	CcSEcCtD
Nefazodone—Dermatitis—Lisinopril—coronary artery disease	2.96e-05	0.00014	CcSEcCtD
Nefazodone—Headache—Lisinopril—coronary artery disease	2.94e-05	0.000139	CcSEcCtD
Nefazodone—Nausea—Lisinopril—coronary artery disease	2.79e-05	0.000132	CcSEcCtD
Nefazodone—CYP3A4—Metabolism—ALDH2—coronary artery disease	2.65e-06	2.66e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PPARGC1A—coronary artery disease	2.65e-06	2.65e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—AGT—coronary artery disease	2.65e-06	2.65e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—CCL2—coronary artery disease	2.65e-06	2.65e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—HMOX1—coronary artery disease	2.64e-06	2.64e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Hemostasis—AKT1—coronary artery disease	2.64e-06	2.64e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—IL6R—coronary artery disease	2.64e-06	2.64e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—FN1—coronary artery disease	2.64e-06	2.64e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—F2—coronary artery disease	2.64e-06	2.64e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—IL6ST—coronary artery disease	2.63e-06	2.63e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—GSTM1—coronary artery disease	2.61e-06	2.61e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—CAT—coronary artery disease	2.61e-06	2.61e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—NFKBIA—coronary artery disease	2.61e-06	2.61e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—IGF1—coronary artery disease	2.6e-06	2.6e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—APOE—coronary artery disease	2.6e-06	2.6e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—LEP—coronary artery disease	2.6e-06	2.6e-05	CbGpPWpGaD
Nefazodone—HTR1A—GPCR downstream signaling—PIK3CA—coronary artery disease	2.6e-06	2.6e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—SERPINE1—coronary artery disease	2.59e-06	2.6e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—MAPK1—coronary artery disease	2.59e-06	2.59e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—HBA1—coronary artery disease	2.59e-06	2.59e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—LIPC—coronary artery disease	2.59e-06	2.59e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PIK3C2A—coronary artery disease	2.59e-06	2.59e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—CYP2C19—coronary artery disease	2.59e-06	2.59e-05	CbGpPWpGaD
Nefazodone—HTR2C—GPCR downstream signaling—PIK3CA—coronary artery disease	2.58e-06	2.59e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—SERPINE1—coronary artery disease	2.58e-06	2.58e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—KIT—coronary artery disease	2.58e-06	2.58e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—APOC3—coronary artery disease	2.57e-06	2.57e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—APOA1—coronary artery disease	2.57e-06	2.57e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—LPL—coronary artery disease	2.56e-06	2.56e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—LDLR—coronary artery disease	2.56e-06	2.56e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—KDR—coronary artery disease	2.54e-06	2.55e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—APOB—coronary artery disease	2.53e-06	2.53e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—MAPK14—coronary artery disease	2.53e-06	2.53e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—SLC9A1—coronary artery disease	2.53e-06	2.53e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—GSTT1—coronary artery disease	2.53e-06	2.53e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—KIT—coronary artery disease	2.52e-06	2.52e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—FGF2—coronary artery disease	2.51e-06	2.51e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—GPX1—coronary artery disease	2.5e-06	2.5e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—FGF2—coronary artery disease	2.5e-06	2.5e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—GCLC—coronary artery disease	2.5e-06	2.5e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—CETP—coronary artery disease	2.5e-06	2.5e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—ESR1—coronary artery disease	2.48e-06	2.48e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—PPARG—coronary artery disease	2.48e-06	2.48e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—NOS3—coronary artery disease	2.48e-06	2.48e-05	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR downstream signaling—PIK3CA—coronary artery disease	2.47e-06	2.47e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—GSK3B—coronary artery disease	2.47e-06	2.47e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—SERPINE1—coronary artery disease	2.47e-06	2.47e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—SDC1—coronary artery disease	2.47e-06	2.47e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—NOS3—coronary artery disease	2.46e-06	2.46e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—GSTM1—coronary artery disease	2.46e-06	2.46e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—POMC—coronary artery disease	2.45e-06	2.45e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CREB1—coronary artery disease	2.45e-06	2.45e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—FN1—coronary artery disease	2.45e-06	2.45e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—F2—coronary artery disease	2.45e-06	2.45e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—POMC—coronary artery disease	2.45e-06	2.45e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—IL6ST—coronary artery disease	2.44e-06	2.44e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—CD36—coronary artery disease	2.43e-06	2.44e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—ALB—coronary artery disease	2.43e-06	2.43e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—GSK3B—coronary artery disease	2.42e-06	2.42e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—NFKBIA—coronary artery disease	2.42e-06	2.42e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—LPL—coronary artery disease	2.41e-06	2.42e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—JAK2—coronary artery disease	2.41e-06	2.41e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—PPP2CA—coronary artery disease	2.4e-06	2.41e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—POMC—coronary artery disease	2.4e-06	2.4e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CREB1—coronary artery disease	2.4e-06	2.4e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CCL2—coronary artery disease	2.4e-06	2.4e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—JAK2—coronary artery disease	2.39e-06	2.4e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—IL6R—coronary artery disease	2.39e-06	2.39e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—FGF2—coronary artery disease	2.39e-06	2.39e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—IGF1—coronary artery disease	2.36e-06	2.36e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—PIK3CA—coronary artery disease	2.36e-06	2.36e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—NOS3—coronary artery disease	2.36e-06	2.36e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—GPX1—coronary artery disease	2.36e-06	2.36e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CCL2—coronary artery disease	2.35e-06	2.35e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—MAPK1—coronary artery disease	2.35e-06	2.35e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—PIK3CA—coronary artery disease	2.35e-06	2.35e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—KIT—coronary artery disease	2.34e-06	2.35e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—IL6R—coronary artery disease	2.34e-06	2.34e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PSMB5—coronary artery disease	2.33e-06	2.33e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PSMA6—coronary artery disease	2.33e-06	2.33e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—NOS3—coronary artery disease	2.33e-06	2.33e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—IGF1—coronary artery disease	2.31e-06	2.31e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—MTHFR—coronary artery disease	2.31e-06	2.31e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—MAPK1—coronary artery disease	2.3e-06	2.3e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—CD36—coronary artery disease	2.29e-06	2.3e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—JAK2—coronary artery disease	2.29e-06	2.29e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—CTGF—coronary artery disease	2.28e-06	2.28e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PPP2CA—coronary artery disease	2.27e-06	2.27e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—GOT2—coronary artery disease	2.26e-06	2.26e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—HMGCR—coronary artery disease	2.26e-06	2.26e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—GSK3B—coronary artery disease	2.25e-06	2.25e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—PIK3CA—coronary artery disease	2.25e-06	2.25e-05	CbGpPWpGaD
Nefazodone—HTR2A—GPCR downstream signaling—PIK3CA—coronary artery disease	2.24e-06	2.25e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—SERPINE1—coronary artery disease	2.24e-06	2.24e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—POMC—coronary artery disease	2.23e-06	2.23e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CREB1—coronary artery disease	2.23e-06	2.23e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—ALB—coronary artery disease	2.23e-06	2.23e-05	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR downstream signaling—PIK3CA—coronary artery disease	2.2e-06	2.2e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—CXCL8—coronary artery disease	2.2e-06	2.2e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—SERPINE1—coronary artery disease	2.19e-06	2.2e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—AGT—coronary artery disease	2.19e-06	2.19e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—CXCL8—coronary artery disease	2.18e-06	2.19e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CCL2—coronary artery disease	2.18e-06	2.18e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—IL6R—coronary artery disease	2.18e-06	2.18e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—MTHFR—coronary artery disease	2.17e-06	2.18e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—FGF2—coronary artery disease	2.17e-06	2.17e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—APOE—coronary artery disease	2.15e-06	2.15e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—IGF1—coronary artery disease	2.15e-06	2.15e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—NOS3—coronary artery disease	2.14e-06	2.14e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—MAPK1—coronary artery disease	2.14e-06	2.14e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—NOS3—coronary artery disease	2.13e-06	2.13e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—PTGS2—coronary artery disease	2.13e-06	2.13e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—FGF2—coronary artery disease	2.12e-06	2.13e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—APOA1—coronary artery disease	2.12e-06	2.12e-05	CbGpPWpGaD
Nefazodone—HTR1A—GPCR downstream signaling—AKT1—coronary artery disease	2.12e-06	2.12e-05	CbGpPWpGaD
Nefazodone—HTR2C—GPCR downstream signaling—AKT1—coronary artery disease	2.11e-06	2.11e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—CASP3—coronary artery disease	2.1e-06	2.1e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—NOS3—coronary artery disease	2.09e-06	2.1e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—CXCL8—coronary artery disease	2.09e-06	2.09e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—CASP3—coronary artery disease	2.09e-06	2.09e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—IL6—coronary artery disease	2.09e-06	2.09e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—JAK2—coronary artery disease	2.08e-06	2.08e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—IL6—coronary artery disease	2.08e-06	2.08e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PLCB1—coronary artery disease	2.08e-06	2.08e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—AGT—coronary artery disease	2.07e-06	2.07e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—CCND1—coronary artery disease	2.05e-06	2.05e-05	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—PIK3CA—coronary artery disease	2.04e-06	2.04e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—SERPINE1—coronary artery disease	2.04e-06	2.04e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—PIK3CA—coronary artery disease	2.04e-06	2.04e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—JAK2—coronary artery disease	2.04e-06	2.04e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—CCND1—coronary artery disease	2.04e-06	2.04e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—APOE—coronary artery disease	2.02e-06	2.03e-05	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR downstream signaling—AKT1—coronary artery disease	2.02e-06	2.02e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—ABCA1—coronary artery disease	2.01e-06	2.01e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—CASP3—coronary artery disease	2e-06	2e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—APOA1—coronary artery disease	2e-06	2e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—PIK3CA—coronary artery disease	2e-06	2e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—IL6—coronary artery disease	1.99e-06	1.99e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—MMP9—coronary artery disease	1.99e-06	1.99e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—MMP9—coronary artery disease	1.98e-06	1.98e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—FGF2—coronary artery disease	1.97e-06	1.97e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—PTGS2—coronary artery disease	1.95e-06	1.95e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—GGT1—coronary artery disease	1.95e-06	1.95e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—GOT1—coronary artery disease	1.95e-06	1.95e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—CCND1—coronary artery disease	1.95e-06	1.95e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—NOS3—coronary artery disease	1.95e-06	1.95e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—AKT1—coronary artery disease	1.93e-06	1.93e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—AKT1—coronary artery disease	1.92e-06	1.92e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CXCL8—coronary artery disease	1.9e-06	1.9e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—MMP9—coronary artery disease	1.89e-06	1.89e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—JAK2—coronary artery disease	1.89e-06	1.89e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—PPARG—coronary artery disease	1.87e-06	1.87e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CXCL8—coronary artery disease	1.86e-06	1.86e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—PIK3CA—coronary artery disease	1.85e-06	1.85e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—POMC—coronary artery disease	1.85e-06	1.85e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—AKT1—coronary artery disease	1.83e-06	1.84e-05	CbGpPWpGaD
Nefazodone—HTR2A—GPCR downstream signaling—AKT1—coronary artery disease	1.83e-06	1.83e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CASP3—coronary artery disease	1.82e-06	1.82e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—IL6—coronary artery disease	1.8e-06	1.81e-05	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR downstream signaling—AKT1—coronary artery disease	1.79e-06	1.8e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—VEGFA—coronary artery disease	1.78e-06	1.78e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CASP3—coronary artery disease	1.78e-06	1.78e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—VEGFA—coronary artery disease	1.77e-06	1.78e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CCND1—coronary artery disease	1.77e-06	1.77e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—IL6—coronary artery disease	1.77e-06	1.77e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PPARG—coronary artery disease	1.76e-06	1.76e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—GSTP1—coronary artery disease	1.75e-06	1.75e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—POMC—coronary artery disease	1.74e-06	1.74e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PPARGC1A—coronary artery disease	1.73e-06	1.74e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CCND1—coronary artery disease	1.73e-06	1.73e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—HMOX1—coronary artery disease	1.73e-06	1.73e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CXCL8—coronary artery disease	1.73e-06	1.73e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—MMP9—coronary artery disease	1.72e-06	1.72e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—CAT—coronary artery disease	1.7e-06	1.7e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—VEGFA—coronary artery disease	1.7e-06	1.7e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—ALB—coronary artery disease	1.68e-06	1.68e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—MMP9—coronary artery disease	1.68e-06	1.68e-05	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—AKT1—coronary artery disease	1.67e-06	1.67e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—AKT1—coronary artery disease	1.66e-06	1.67e-05	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—PIK3CA—coronary artery disease	1.66e-06	1.66e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—APOB—coronary artery disease	1.65e-06	1.65e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CASP3—coronary artery disease	1.65e-06	1.65e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—IL6—coronary artery disease	1.64e-06	1.64e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—TGFB1—coronary artery disease	1.64e-06	1.64e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—AKT1—coronary artery disease	1.63e-06	1.63e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—TGFB1—coronary artery disease	1.63e-06	1.63e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—NOS3—coronary artery disease	1.61e-06	1.61e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—GSTM1—coronary artery disease	1.61e-06	1.61e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CCND1—coronary artery disease	1.61e-06	1.61e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—MAPK1—coronary artery disease	1.61e-06	1.61e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—MAPK1—coronary artery disease	1.6e-06	1.6e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—ALB—coronary artery disease	1.59e-06	1.59e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—LPL—coronary artery disease	1.58e-06	1.58e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—MMP9—coronary artery disease	1.56e-06	1.56e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—TGFB1—coronary artery disease	1.56e-06	1.56e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—VEGFA—coronary artery disease	1.54e-06	1.54e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—GPX1—coronary artery disease	1.54e-06	1.54e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—MAPK1—coronary artery disease	1.53e-06	1.53e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—NOS3—coronary artery disease	1.52e-06	1.52e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—AKT1—coronary artery disease	1.51e-06	1.52e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—VEGFA—coronary artery disease	1.51e-06	1.51e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—CD36—coronary artery disease	1.5e-06	1.5e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PPP2CA—coronary artery disease	1.48e-06	1.48e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—PTGS2—coronary artery disease	1.47e-06	1.47e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—MTHFR—coronary artery disease	1.42e-06	1.42e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—TGFB1—coronary artery disease	1.41e-06	1.42e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—VEGFA—coronary artery disease	1.4e-06	1.4e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—PIK3CA—coronary artery disease	1.39e-06	1.39e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—MAPK1—coronary artery disease	1.39e-06	1.39e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PTGS2—coronary artery disease	1.39e-06	1.39e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—PIK3CA—coronary artery disease	1.39e-06	1.39e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—TGFB1—coronary artery disease	1.38e-06	1.39e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—MAPK1—coronary artery disease	1.36e-06	1.36e-05	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—AKT1—coronary artery disease	1.36e-06	1.36e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—AGT—coronary artery disease	1.35e-06	1.35e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—PIK3CA—coronary artery disease	1.33e-06	1.33e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—APOE—coronary artery disease	1.32e-06	1.32e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—PIK3CA—coronary artery disease	1.31e-06	1.31e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—APOA1—coronary artery disease	1.31e-06	1.31e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—TGFB1—coronary artery disease	1.29e-06	1.29e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—MAPK1—coronary artery disease	1.26e-06	1.26e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—IL6—coronary artery disease	1.23e-06	1.23e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—IL6—coronary artery disease	1.23e-06	1.23e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—PIK3CA—coronary artery disease	1.2e-06	1.2e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—PIK3CA—coronary artery disease	1.2e-06	1.2e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—PIK3CA—coronary artery disease	1.18e-06	1.18e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—IL6—coronary artery disease	1.17e-06	1.18e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PPARG—coronary artery disease	1.15e-06	1.15e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—AKT1—coronary artery disease	1.14e-06	1.14e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—POMC—coronary artery disease	1.14e-06	1.14e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—AKT1—coronary artery disease	1.13e-06	1.13e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—PIK3CA—coronary artery disease	1.1e-06	1.1e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—AKT1—coronary artery disease	1.08e-06	1.08e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—AKT1—coronary artery disease	1.07e-06	1.07e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—IL6—coronary artery disease	1.07e-06	1.07e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—IL6—coronary artery disease	1.04e-06	1.04e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—ALB—coronary artery disease	1.04e-06	1.04e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—NOS3—coronary artery disease	9.92e-07	9.92e-06	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—AKT1—coronary artery disease	9.83e-07	9.84e-06	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—AKT1—coronary artery disease	9.8e-07	9.81e-06	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—IL6—coronary artery disease	9.7e-07	9.7e-06	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—AKT1—coronary artery disease	9.63e-07	9.63e-06	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PTGS2—coronary artery disease	9.07e-07	9.07e-06	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—PIK3CA—coronary artery disease	9.06e-07	9.06e-06	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—AKT1—coronary artery disease	8.95e-07	8.95e-06	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PIK3CA—coronary artery disease	8.53e-07	8.54e-06	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—AKT1—coronary artery disease	7.4e-07	7.4e-06	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—AKT1—coronary artery disease	6.97e-07	6.98e-06	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PIK3CA—coronary artery disease	5.58e-07	5.58e-06	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—AKT1—coronary artery disease	4.56e-07	4.56e-06	CbGpPWpGaD
